The Food and Drug Administration (FDA) has approved Welireg ™ (belzutifan) for the treatment of adult and pediatric patients aged 12 years and older with locally advanced, unresectable, or metastatic ...

Welireg marks the first FDA-approved non-surgical treatment option for locally advanced, unresectable, or metastatic ...

Rahway, New Jersey Friday, May 16, 2025, 13:00 Hrs [IST] ...

Six years after Merck bought out Peloton Therapeutics, the New Jersey drugmaker is not remaining stationary with the crown ...

The U.S. Food and Drug Administration (FDA) on Wednesday approved Merck’s (NYSE:MRK) anti-cancer agent Welireg (belzutifan) ...

MSD's oral HIF-2 alpha inhibitor Welireg has a third FDA approval, becoming the first oral treatment for a rare form of solid ...

The US food and Drug Administration (FDA) has expanded the approval of Belzutifan (Welireg) to treat specific types of ...

Merck's Welireg wins FDA approval for rare PPGL tumors; Q1 2025 sales reach $137M, marking a 62% year-over-year increase.

The US Food and Drug Administration (FDA) has approved belzutifan (Welireg, Merck) for adult and pediatric patients aged 12 ...

The action establishes belzutifan as the only approved oral therapy for PPGL. The approval stipulates use in adults and ...

Bayer BAYRY announced first-quarter 2025 results. Novo Nordisk NVO and GSK plc GSK announced licensing deals with smaller ...

Merck has received approval from the Food and Drug Administration for Welireg, its oral inhibitor for patients with certain rare types of neuroendocrine tumors. The company said Wednesday the ...